Exchange: NASDAQ·Updated 12:00 AM EST

ATXS Astria Therapeutics Inc

$12.56
$0.00
(0.00%)
Pre-Market
Prev Close $12.56
Reported EarningsNov 12
Mkt Cap$718.13M

About ATXS

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
53

Neutral Sentiment

How do you feel about ATXS?

Advertisement|Remove ads.